- •Drug Product Development for the Back of the Eye
- •Preface
- •Contents
- •Contributors
- •1.1 Introduction
- •1.2 A Strategic Overview of Drug Delivery Systems
- •1.3 Specific Approaches to Drug Delivery for the Posterior Segment
- •1.3.1 The Influence of Physicochemical Properties on Drug Delivery and Pharmacokinetics
- •1.3.2 The Chosen Route of Administration
- •1.3.3 Location of the Target Tissue
- •1.3.4 Potency of the Drug
- •1.3.5 Need for Continuous or Pulsatile Delivery
- •1.3.6 Duration of Drug Delivery Necessary to Induce and Maintain Efficacy
- •1.3.7 Type of Drug Delivery System Selected
- •1.3.8 Pharmacokinetic (PK) Properties of the Drug
- •1.3.9 Local and Systemic Toxicity of the Drug and its Metabolites
- •1.3.10 Previous Ocular Use of Excipients
- •1.3.11 Development and Strategic Team Input
- •References
- •2.1 Introduction
- •2.2 Posterior Segment as a Sampling Site
- •2.3 Principle of Microdialysis
- •2.3.1 Extraction Efficiency/Recovery
- •2.4.1 Anesthetized Animal Models
- •2.4.2 Conscious Animal Model
- •2.5 Vitreal Pharmacokinetics in Animals Other than Rabbits
- •2.6 Summary
- •References
- •3.1 Commercial Fluorophotometer
- •3.2 Normal Human Subject and Rabbit Ocular Fluorescence
- •3.3 Fluorophotometry Applications
- •3.3.1 Tear Turnover Rate (%/min)
- •3.3.2 Corneal Epithelial Cell Layer Permeability Methodologies
- •3.3.3 Eye Bath Technique
- •3.3.4 Single Drop Technique to Measure Epithelial Permeability
- •3.3.5 Eye Bath Technique to Measure Epithelial Permeability
- •3.4 Clinical Applications of Fluorophotometry
- •3.5.1 Transscleral Pathways
- •3.5.2 Suprachoroidal Injection
- •3.6 Retrobulbar Fluorescein Injection
- •3.7 Intravenous Fluorescein Injection In Vivo
- •3.8 Ocular Uptake of Fluorescein from Topical Eye Drops
- •References
- •4.1 Introduction
- •4.1.1 Role of the Blood-Retinal Barrier as a Dynamic Interface
- •4.1.2 Potential Approach of Blood-Retinal Barrier-Targeted Systemic Drug Delivery to the Retina
- •4.2.1 Amino Acid-Mimetic Drugs
- •4.2.2 Monocarboxylic Drugs
- •4.2.3 Nucleoside Analogs
- •4.2.4 Folate Analogs
- •4.2.5 Organic Cationic Drugs
- •4.2.6 Opioid Peptides and Peptidomimetic Drugs
- •4.2.7 Antioxidants
- •4.2.7.1 Vitamin C
- •4.2.7.2 Vitamin E
- •4.2.7.3 Cystine
- •4.2.8 Miscellaneous Protective Compounds
- •4.2.8.1 Creatine
- •4.2.8.2 Taurine
- •4.3.1 Organic Anion Transporter 3 (OAT3, SLC22A8)
- •4.3.3 P-Glycoprotein (ABCB1)
- •4.3.4 Multidrug Resistance-Associated Proteins (ABCCs)
- •4.3.6 ABCAs
- •4.4 Conclusions and Perspectives
- •References
- •5.1 Introduction
- •5.2 Drug Distribution
- •5.2.1 Drug Distribution from the Anterior Ocular Surface to the Posterior Segment
- •5.2.2 Studies of Trans-Corneal and Periocular Drug Delivery to the Retina
- •5.2.2.1 The Uvea-Scleral Route
- •5.3 Eye Drops for Posterior Segment Diseases in the Clinic
- •5.4 Summary
- •References
- •6.1 Introduction
- •6.2 Vitreous Anatomy
- •6.2.1 The Inner Limiting Membrane
- •6.3 The Vitreous As a Drug Reservoir
- •6.4 Flow Processes in the Vitreous
- •6.4.1 Flow Patterns
- •6.4.2 Injection and Hydrostatic Effects
- •6.4.3 Diffusion
- •6.4.4 Convective Flow
- •6.5 Clearance Pathways from the Vitreous Compartment
- •6.5.1 Charge and Collagen Interaction
- •6.5.2 Aqueous Clearance
- •6.5.3 Retinal Clearance
- •6.6 Transfer Through the Vitreoretinal Border
- •6.6.1 The Role of the Blood–Retinal Barrier
- •6.6.1.1 Amino Acid Transport
- •6.6.1.2 P-Glycoprotein
- •6.6.1.3 Organic Cationic Transporters
- •6.6.1.4 Organic Anion Transporters
- •6.6.1.5 Other Transporters
- •6.7 The Ageing Vitreous
- •6.7.1 Underlying Mechanisms of Vitreous Degeneration
- •6.7.2 Physical Changes Involved in the Ageing Vitreous
- •6.7.2.1 Pre-Clinical Model of Ageing Vitreous
- •6.7.2.2 Effects of Vitreous Liquefaction on Intravitreal Drug Delivery
- •6.7.3 Vitrectomised Eyes
- •6.7.3.1 Intravitreal Drug Distribution and Clearance in Silicone Oil
- •6.7.4 Role of Ocular Movements in Disordered Vitreous
- •6.8 Concluding Remarks
- •References
- •7.1 Introduction
- •7.2 Drug Delivery to Posterior Segment Ocular Tissues
- •7.3 Scleral Structure and Drug Delivery
- •7.4 Scleral Permeability: Initial Studies
- •7.5 Sustained-Release Delivery In Vitro
- •7.6 In Vivo Studies
- •7.7 Conclusions and Future Directions
- •References
- •8.1 Introduction
- •8.2 Background
- •8.3 Posterior Segment Delivery
- •8.4 Transscleral and Intrascleral Drug Delivery
- •8.5 Suprachoroidal Drug Delivery
- •8.6 Summary
- •References
- •9.1 Introduction
- •9.2 Nonbiodegradable Ocular Drug Delivery Systems
- •9.2.1 Retisert
- •9.2.2 Ocusert
- •9.2.3 Vitrasert
- •9.2.4 I-vation
- •9.2.5 Iluvien
- •9.2.6 Nonbiodegradable Matrix Implants
- •9.2.6.2 Punctal Plugs
- •9.3 Medical Applications for Biodegradable Polymers
- •9.3.3 Poly(Ortho Esters)
- •9.3.4 Polyanhydrides
- •9.5.1 Ozurdex™
- •9.5.2 Surodex
- •9.5.3 Verisome
- •9.5.4 Lacrisert
- •9.6.1 Poly(Lactic Acid)-Based Implants
- •9.6.2 PLGA-Based Implants
- •9.6.5 Poly(Ortho Ester)-Based Implants
- •9.6.6 Polyanhydride-Based Implants
- •9.6.7 Other Biodegradable Polymer-Based Implants
- •9.7 Conclusions
- •References
- •10.1 Introduction
- •10.2 Manufacturing of Microparticles
- •10.3 Characterization of Microparticles
- •10.3.1 Morphological Characterization of Microparticles
- •10.3.2 Particle Size Analysis and Distribution
- •10.3.3 Infrared Absorption Spectrophotometry (IR)
- •10.3.4 Differential Scanning Calorimetry (DSC)
- •10.3.5 X-Ray Diffraction
- •10.3.6 Gel Permeation Chromatography (GPC)
- •10.3.7 Determination of Drug Loading Efficiency
- •10.3.8 “In Vitro” Release Studies
- •10.3.8.1 Additives in Microspheres
- •10.4 Sterilization of Microparticles
- •10.5 Calculation of the Dose of Microparticles for Injection
- •10.6 Injectability Studies
- •10.7 In Vivo Studies
- •10.7.1 In Vivo Injection of Microparticles
- •10.7.2 Ocular Disposition and Cellular Uptake
- •10.7.3 Tolerance of Microparticles
- •10.7.4 In Vivo Degradation of PLA and PLGA Microparticles
- •10.8 In Vitro and In Vivo Correlation
- •10.9 Microparticles for the Treatment of Posterior Segment Diseases. Animal Models and Human Studies
- •10.9.1 Proliferative Vitreoretinopathy (PVR)
- •10.9.2 Uveitis
- •10.9.3 Age-Related Macular Degeneration (AMD)
- •10.9.4 Diabetic Retinopathy
- •10.9.5 Macular edema
- •10.9.6 Acute Retinal Necrosis (ARN)
- •10.9.7 Cytomegalovirus (CMV) Retinitis
- •10.9.8 Choroidal Neovascularization
- •10.9.9 Diseases Affecting the Optic Nerve
- •10.9.11 Microparticles in Retinal Repair
- •10.10 Conclusions
- •References
- •11.1 Introduction
- •11.2 Nanoparticles
- •11.2.1 Polymer Nanoparticles
- •11.2.2 Liposomes and Lipid Nanoparticles
- •11.2.3 Micelles
- •11.2.4 Protein Nanoparticles
- •11.2.5 Carbohydrate Nanoparticles
- •11.2.6 Dendrimers
- •11.2.7 Combination Nanosystems
- •11.3 Using Nanotechnology to Improve Ocular Therapeutics
- •11.3.1 Improving Patient Compliance
- •11.3.2 Increasing Drug Retention and Sustained Release
- •11.3.3 Increasing Permeability and Tissue Partitioning
- •11.3.4 Targeting Nanotherapies
- •11.3.5 Intracellular Trafficking
- •11.4 Alternative Approaches to Improve Ocular Therapeutics
- •11.5 Conclusion
- •References
- •12.1 Introduction
- •12.2 Hydrogel Technology
- •12.6 Future Directions
- •References
- •13.1 Introduction
- •13.2 General Design Considerations
- •13.2.1 Administration Site
- •13.2.2 Body Design
- •13.2.3 Port Design
- •13.2.4 Vacuum and Pressure
- •13.2.5 Flushing and Fluid Replacement
- •13.2.5.1 Active Pumps
- •13.2.5.2 Passive Systems
- •13.2.5.3 Solid Refill
- •13.2.6 Contamination Potential
- •13.3 Historical Influences
- •13.3.1 Infusion Pumps
- •13.3.2 Glaucoma Drainage Devices
- •13.3.3 Pioneering of Refill Procedure in the Eye
- •13.4 Ophthalmic Refillable Devices
- •13.4.1 Invasiveness and Refilling Frequency
- •13.4.2 Intravitreal Delivery Through the Pars Plana
- •13.4.3 Episcleral Implantation for Trans-Scleral Delivery
- •13.4.4 Subretinal and Suprachoroidal Implantation
- •13.4.5 Lens Capsule Delivery
- •13.5 Conclusions
- •References
- •14.1 Introduction
- •14.2 Current Methods of Drug Delivery to the Eye
- •14.3 Improved Methods of Drug Delivery to the Eye Using Microneedles
- •14.3.1 Intrastromal Delivery to the Cornea Using Coated Microneedles
- •14.3.3 Suprachoroidal Delivery Using Hollow Microneedles
- •14.4 Microneedle Types and Other Applications
- •14.4.1 Poke and Apply
- •14.4.2 Coat and Poke
- •14.4.3 Poke and Release
- •14.4.4 Poke and Flow
- •14.5 Discussion
- •14.6 Conclusion
- •References
- •15.1 Introduction
- •15.1.1 General Mechanisms of Iontophoretic Drug Delivery
- •15.1.2 The Shunt Pathway
- •15.1.3 The Flip–Flop Gating Mechanism
- •15.1.4 Electro-Osmosis
- •15.2 Ocular Drug Delivery: The Past and the Future
- •15.3 Ophthalmic Applications of Iontophoresis
- •15.3.1 Transconjunctival Iontophoresis
- •15.3.1.1 Transconjunctival Iontophoresis of Antimitotics
- •15.3.1.2 Transconjunctival Iontophoresis of Anesthetics
- •15.3.2 Transcorneal Iontophoresis
- •15.3.2.1 Transcorneal of Fluorescein Iontophoresis for Aqueous Humor Dynamic Studies
- •15.3.2.2 Transcorneal Iontophoresis of Antibiotics
- •15.3.2.3 Transcorneal Iontophoresis of Antiviral Drugs
- •15.3.2.4 Other Drugs for Transcorneal Iontophoresis
- •15.3.2.5 Is Transcorneal Iontophoresis Safe?
- •15.4 Transscleral Iontophoresis
- •15.4.1 Transscleral Iontophoresis of Antibiotics
- •15.4.2 Transscleral Iontophoresis of Antiviral Drugs
- •15.4.3 Transscleral Iontophoresis of Anti-Inflammatory Drugs
- •15.4.3.1 Aspirin
- •15.4.3.2 Glucocorticoids
- •15.4.3.3 Transscleral Iontophoresis of Carboplatin
- •15.4.3.4 Is Transscleral Iontophoresis Safe?
- •15.4.3.5 Transscleral Iontophoresis for High Molecular Weight Compounds and Proteins
- •15.4.3.6 Clinical Application of Transscleral Iontophoresis
- •15.5 Applications of Iontophoresis to Ocular Gene Therapy
- •15.6 Future Developments
- •References
- •16.1 Introduction
- •16.2 Background
- •16.2.1 Intravitreal Injections
- •16.2.2 Impact of Genetics
- •16.3 Better Tools for Delivery and Treatment
- •16.3.1 Barriers to Success
- •16.3.2 Physics-Based Approaches
- •16.3.2.1 Physical Methods to Deliver Drugs to a Target Cell in the Posterior Segment
- •16.3.2.2 History of Electrical Fields in Medicine
- •16.3.2.3 Safety Concerns with Electric Fields
- •16.3.2.4 Definitions of Electric Field Methods
- •16.3.2.5 Advantages of Electric Fields for DNA Transfection vs. Viral Mediated DNA Delivery
- •16.3.2.6 Problems of In Vivo Electric Field Applications
- •16.3.2.7 Possible Strategies to Improve Electric Field-Mediated Drug Delivery
- •16.3.3 Experiences with Iontophoresis
- •16.3.3.1 Examples of Iontophoresis
- •16.3.3.2 Summary of the Strengths and Weaknesses of Iontophoresis
- •16.3.4 Experiences with Electroporation
- •16.3.4.1 Examples of Electroporation in Living Animals
- •16.3.4.2 Strengths and Weaknesses of Electroporation
- •16.4 Outstanding Issues in Electric Fields for the Delivery of Drugs
- •16.5 Summary
- •References
- •17.1 Introduction
- •17.2 Routes of Protein Administration
- •17.2.1 Topical
- •17.2.2 Intracameral
- •17.2.3 Intravitreal
- •17.2.4 Periocular (Transscleral)
- •17.2.5 Suprachoroidal
- •17.2.6 Subretinal
- •17.2.7 Systemic
- •17.3 Advantages and Challenges of Protein Delivery
- •17.4 Current Development Strategies
- •17.4.1 Pure Protein
- •17.4.2 PEGylation
- •17.4.4 Liposomes
- •17.4.5 Stem Cells
- •17.4.6 Implants
- •17.5 Case Studies
- •17.6 Ophthalmic Protein Formulation Development
- •17.6.1 Protein Biosynthesis
- •17.6.2 Preformulation Studies
- •17.6.3 Selection of Excipients
- •17.6.4 Optimization of Process Variables
- •17.7 Specifications and Regulatory Guidelines
- •17.8 Conclusions
- •References
- •18.1 Need for Suspension Development for the Back of the Eye
- •18.2 Background
- •18.3 Development of Drug Suspensions Intended for the Back of the Eye
- •18.3.1 Drug Suspensions
- •18.3.1.1 Physical Pharmacy Principles that Explain the Stability and Formulation of Suspensions
- •18.3.1.2 Formulation Methodology
- •18.3.1.3 Manufacturing Process
- •18.3.2 Factors To Be Considered in Suspension Development for the Back of the Eye
- •18.3.2.1 Formulation Development and Evaluation
- •18.3.2.2 In Situ Forming Suspensions, Selection of Drug Form for Suspension, and Polymeric Microparticle Suspension
- •18.3.2.3 Clinical Studies on Safety
- •18.4 Conclusions
- •References
- •19.1 Introduction
- •19.2 Drug Product Approval Process
- •19.3 Considerations for Back of the Eye Treatments
- •19.4 Adaptive Trial Design
- •19.5 Drug-Device Combinations
- •19.6 Product Summary Basis of Approval Reviews
- •19.6.1 OZURDEX™
- •19.6.2 LUCENTIS™
- •19.7 Summary
- •References
- •20.1 Background
- •20.2 FDA Endpoints
- •20.3 Endpoints for Neovascular Age-Related Macular Degeneration (Table 20.1)
- •20.4 FDA Guidelines for Other Retinal Diseases
- •20.5 Endpoint for Geographic Atrophy
- •20.6 Endpoint for Retinal Vein Occlusion
- •20.7 Future Endpoints
- •References
- •21.1 Introduction
- •21.2 Ocular Physiology and Pathology
- •21.2.1 Ocular Inflammation
- •21.2.2 Neovascularization
- •21.2.3 Degeneration
- •21.3 Current Therapies for Key Back of the Eye Disorders
- •21.3.1 Age-Related Macular Degeneration
- •21.3.1.1 Pathophysiology
- •21.3.1.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.3.1.3 Current Research Focused on Identifying New Targets
- •21.3.2 Diabetic Retinopathy
- •21.3.2.1 Pathophysiology
- •21.3.2.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.3.3 Retinopathy of Prematurity
- •21.3.3.1 Pathophysiology
- •21.3.3.2 Therapeutics Either in Current Use and in Clinical Trials
- •21.3.4 Degenerative Conditions
- •21.3.4.1 Pathophysiology
- •21.3.4.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.3.5 Opportunistic Infections
- •21.3.5.1 Pathophysiology
- •21.3.5.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.3.6 Autoimmune Disease
- •21.3.6.1 Pathophysiology
- •21.3.6.2 Therapeutics Either in Current Use or in Clinical Trials
- •21.4 Conclusion
- •References
- •22.1 Bile Acids as Anti-Apoptotic Neuroprotectants
- •22.3 Potential Need for Local Delivery of Bile Acids as Neuroprotectants
- •22.4 Preliminary Studies of Ocular Delivery of Bile Acids
- •22.5 Conclusion
- •References
- •Index
232 |
R. Herrero-Vanrell |
Mw |
Weight-average molecular weight |
Mn |
Number-average molecular weight |
PEG |
Polyethylene glycol |
kGy |
Kilo Gray |
Tg |
Glass transition temperature |
Tm |
Crystalline melting points |
Css |
Steady state concentration |
K0 |
Zero-order constant |
Vd |
Volume of the vitreous |
Ke |
Elimination rate constant |
G |
Gauge |
PBS |
Phosphate buffer solution |
BSS |
Buffer solution |
HA |
Hyaluronic acid |
HPMC |
Hydroxypropylmethyl cellulose |
AUC |
Area under the curve |
5-FU |
5-fluorouracil |
VEGF |
Vascular Endothelial Growth Factor |
AMD |
Age macular degeneration (AMD) |
TA |
Triamcinolone acetonide |
PVR |
Proliferative vitreoretinopathy |
RPE |
Retinal pigment epithelium |
RD |
Retinal detachment |
RA |
Retinoic acid |
LPS |
Lipopolysaccharide |
TRD |
Tractional retinal detachment |
CyS |
Cyclosporine |
CNV |
Choroidal neovascularization |
ARN |
Acute retinal necrosis |
HSV |
Herpes simplex virus |
Da |
Daltons |
CMV |
Cytomegalovirus |
HCMV |
Human cytomegalovirus |
RGC |
Retinal ganglion cells (RGC) |
ECM |
Extracellular matrix |
MMP2 |
Matrix metalloproteinase |
RPCs |
Retinal progenitor cells (RPCs) |
10.1 Introduction
Successful ophthalmic therapy requires effective concentrations of the drug in the target site. Therapeutic concentrations of the active substance in cornea and conjunctiva are mandatory for the treatment of ocular surface diseases such as dry eye syndrome, surface inflammation, or infection. However, if the drug has to reach the
10 Microparticles as Drug Delivery Systems for the Back of the Eye |
233 |
aqueous humor as it is the case of hypotensive agents for glaucoma management, the active substance must be present at high concentrations at the site of administration to cross through the cornea and/or conjunctiva to achieve therapeutic concentrations in the anterior segment (only 5% of the administered dose penetrates the cornea) (Maurice and Mishima 1984). Furthermore, the drug must have specific physical and chemical properties to cross the ocular surface barriers. While lipophilic drugs cross the epithelium well, hydrophilic substances are able to cross the stroma. In any case, the molecular weight of the substance must be small enough to use the transcellular or paracellular route to reach intraocular structures.
In the management of vitreoretinal disorders, the drug must reach the back of the eye. In these cases, periocular, intravitreous, or other intraocular injections are required. If successive administrations are needed, special care has to be taken to avoid fibrosis and inflammation at the site of injection. Moreover, it is well known that repeated intravitreal injections are poorly tolerated and the risk of adverse effects (e.g., cataracts, intravitreal hemorrhages, and retinal detachment) increases with the number of administrations (Herrero-Vanrell and Refojo 2001).
Controlled drug delivery systems can maintain concentrations of the active substance at the target site for long periods of time. Among them, implants (>1 mm), microparticles (1–1,000 mm), and nanoparticles (1–1,000 nm) have been developed for the treatment of posterior segment pathologies (Herrero-Vanrell and Refojo 2001; Urtti 2006) (Fig. 10.1).
Fig. 10.1 Strategies to avoid frequent intraocular injections. “Depot” systems – Poor aqueous soluble drugs. Once injected, the active substance is slowly dissolved in the vitreous. Drug delivery systems (DDS): Implants, microparticles, and nanoparticles. Biodegradable DDSs disappear from the site of administration after delivering the drug
234 |
R. Herrero-Vanrell |
Fig. 10.2 Administration routes of microparticles: Intravitreal, subretinal, and periocular
Microparticles are adequate for the intraocular route, bypassing the blood–ocular barrier. One of their advantages is that microparticles can release the drug over the time with one single administration, having the same effect than multiple injections (Fig. 10.2). Furthermore, injection of microparticles is carried out as a conventional suspension.
Microparticles are usually prepared with a polymer or mixture of polymers and one or several active substances. Depending on the nature of the polymer (erodible or biodegradable and nonerodible or nonbiodegradable) microparticles remain or disappear from the site of injection after delivering the drug. In the case of posterior segment diseases, biodegradable microparticles are preferred.
Microparticles are capable to provide sustained and controlled release of the bioactive agent, while the remaining drug still present inside the particle is protected from degradation and physiological clearance.
By physical structure, microparticles are classified in microcapsules and microspheres. Microcapsules are constituted by a drug core, which is surrounded by a polymer layer (reservoir structure). Conversely, in the microspheres the drug is dispersed through the polymeric network (matrix structure) (Fig. 10.3).
Among the biodegradable polymers employed to prepare microparticles are gelatin, albumin, polyorthoesters, polyanhydrides, and polyesters (Colthrust et al. 2000; Herrero-Vanrell and Refojo 2001). Since several years ago, the most employed polymers to prepare biodegradable microspheres are the poly(lactic) acid (PLA), poly(glycolic) acid (PGA), and their copolymers poly(lactic-co-glycolic) acid (PLGA). PLA and PGA have crystalline structure whereas PLGA is amorphous. Experience has shown that the PLGA 50:50 (50% lactide and 50% glycolide) degrades relatively fast to metabolic lactic and glycolic acid that are readily eliminated from the body after suffering metabolism to carbon dioxide and water mediated by Krebs cycle (Zimmer and Kreuter 1995). Regarding to molecular weight, polymers with small chains degrade faster than high molecular weight polymers. For the back of the eye, PLA and PLGA polymers have been employed to prepare different devices: implants, scleral plugs, pellets, discs, films, and rods (Yasukawa et al. 2004; Mansoor et al. 2009).
10 Microparticles as Drug Delivery Systems for the Back of the Eye |
235 |
Fig. 10.3 Structure of microparticles. Microcapsules (reservoir system) and microspheres (matrix structure)
10.2 Manufacturing of Microparticles
Manufacturing of microparticles are mainly based on four basic techniques: aggregation by pH adjustment or heat, coacervation (phase separation), spray drying, and solvent extraction/evaporation (Freitas et al. 2005). Coacervation required the use of solvents and coacervating agents that can remain in the microparticles once prepared and low micrometer size is difficult to obtain. The use of supercritical gases as phase separating agents has been introduced to avoid potentially harmful residues in the microspheres. Spray drying is relatively simple but not useful for highly tem- perature-sensitive drugs. Microspheres prepared according to this technique are highly porous. Microspheres loaded with triamcinolone acetonide (TA) and ciprofloxacin have been prepared by the spray drying technique for intraocular injection (Paganelli et al. 2009).
The most commonly reported technique for microspheres formation is the solvent extraction/evaporation method (evaporation of a solvent from an emulsion) (Herrero-Vanrell et al. 2000; Amrite et al. 2006) (Fig. 10.4). It requires a dissolution or dispersion of the active substance in a first solvent containing the matrix forming polymer (inner phase). After that, an emulsification of the polymer organic solution in a second continuous phase immiscible with the inner phase is carried out. Then, an extraction of the organic solvent from the formed emulsion by evaporation is
236
O/W emulsion
Drug |
O-phase: |
|
PLGA solution |
||
Drug (dissolved) |
||
in CH2CI2 |
||
+PLGA solution |
||
|
in CH2CI2 |
S/O/W emulsion
R. Herrero-Vanrell
|
Dissolved |
|
drug |
Addition of |
O/W emulsion |
aqueous-phase |
|
(PVA 2% in H2O) |
|
|
|
|
Solid |
|
|
|
drug |
PLGA solution |
O-phase: |
Addition of |
S/O/W emulsion |
in CH2CI2 |
drug (solid) + |
aqueous-phase |
|
|
PLGA solution |
(PVA 2% in H2O) |
|
|
in CH2CI2 |
|
|
Preparation of drug dispersion
Solid |
Sonication |
Homogeneous |
drug |
drug solid |
|
|
↓Ta (ice) |
dispersion |
|
↓t(30") |
|
|
↓power |
|
Fig. 10.4 Schematic procedure for microspheres preparation according to solvent/extraction/ evaporation technique (O/W emulsion and S/O/W emulsion) O/W emulsion – The drug is dissolved in the inner phase of the emulsion S/O/W emulsion – The drug is suspended as solid in the inner phase of the emulsion
performed at room temperature or under vacuum. Finally, the immature microspheres are harvested and dried before freeze-drying or desiccation. Lyophilization is preferred because the stability of the product increased. Depending on the solubility of the drug, oil in water (O/W) or oil in oil (O/O) emulsions are formed. In the case of aqueous soluble drugs an (O/O) emulsion achieves higher encapsulation efficiencies. By the contrary, for poor soluble drugs the O/W emulsion technique
